Drug Discovery

A new compound, AP503, has been shown to strengthen bones and muscles in mice by activating the GPR133 receptor, offering potential for osteoporosis treatment.

Scientists found that an experimental compound, AP503, strengthened bones in mice by activating the GPR133 receptor, offering a new approach to fight osteoporosis.

An experimental compound called TOFA helped obese mice burn fat, preserve muscle, and improve metabolic health, offering a new approach to obesity treatment.

Vanderbilt researchers developed two new compounds to study the TAOK protein family, linked to Alzheimer's disease, potentially revealing new disease mechanisms and treatment strategies.

Scientists at ETH Zurich identified a new Alzheimer's trigger and developed an experimental compound that slowed nerve cell loss and extended lifespan in mice.

Researchers developed a light-powered method to create high-energy "housane" molecules, which are valuable for drug development and materials science.